Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity
Biotechnology, Inc. (the "Company") with the Securities and Exchange Commission
on April 11, 2023. As reported on April 11, 2023, the Company and Jamie
Dananberg agreed that Dr. Dananberg would be leaving his employment with the
Company on April 30, 2023. In connection with his departure as an employee on
April 30, 2023, the Company and Dr. Dananberg entered into a Separation
Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will receive,
in addition to any accrued obligations, (i) a severance payment equal to nine
months of his base salary in a lump sum payment and (ii) continued health care
coverage for himself and his covered dependents under the provisions of the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, until the
earlier of the nine month anniversary of his separation date or the date he
becomes eligible for healthcare coverage from another employer. Dr. Dananberg
has agreed to provide a full release of claims in favor of the Company. In
addition, the Company and Dr. Dananberg entered into a Consulting Agreement,
dated April 27, 2023, pursuant to which Dr. Dananberg will continue to provide
advice and assistance with the Company's clinical development programs and
related matters in exchange for continued vesting of his equity awards and
compensation at the rate of $500 per hour for services rendered above and beyond
a monthly eight-hour threshold.
The foregoing is only a summary of the material terms of the Separation
Agreement and the Consulting Agreement and is qualified in its entirety by
reference to the respective agreements, which the Company expects to file as
exhibits to its Quarterly Report on Form 10-Q for the quarter ended March 31,
2023.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
UNITY BIOTECHNOLOGY, INC. 
